{"meta":{"query_hash":"84677f5bcbd6","filters":{"venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine"},"cohort_total":8,"direct_labels_cover":0,"predictions_cover":8,"exported":8,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/84677f5bcbd6","api":"https://metacan.xera.ac/api/v1/cohort?venue=Clinical+Medicine+Insights+Circulatory+Respiratory+and+Pulmonary+Medicine"},"results":[{"id":"W1603911300","doi":"10.1177/117954842020100401","title":"The DNR Order: What Does it Mean?","year":2010,"lang":"en","type":"article","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"Palliative Care and End-of-Life Issues","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of British Columbia","funders":"","keywords":"Pace; Demise; Dignity; Order (exchange); Entitlement (fair division); Medicine; Psychology; Political science; Business; Law; Economics","score_opus":0.1631679095415284,"score_gpt":0.4409797314572354,"score_spread":0.27781182191570697,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1603911300","genre_codex":"commentary","genre_gemma":"commentary","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"commentary","genre_consensus":"commentary","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.0015204313,0.021746535,0.0025576658,0.9316717,0.02338876,0.00003059412,0.00007669716,0.00008793196,0.01891974],"genre_scores_gemma":[0.10765924,0.095841,0.0106843645,0.7239594,0.045051277,0.00036605605,0.0003084824,0.00042453164,0.015705721],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.9768411,0.012445009,0.0018227266,0.00127528,0.0061832583,0.0014325503],"domain_scores_gemma":[0.96623856,0.012919678,0.003659891,0.0019915367,0.009652465,0.005537885],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.015940344,0.0007640931,0.0012863274,0.0019905062,0.0072295326,0.012164594,0.002904856,0.010129289,0.004192448],"category_scores_gemma":[0.062021572,0.00047650293,0.00069995155,0.002486849,0.02471844,0.015611798,0.0043533533,0.01875086,0.003695754],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009290197,0.00011471348,0.003701526,0.0011415588,0.000020366966,0.00077994005,0.009492083,0.00021865036,0.00024070939,0.32497197,0.5303325,0.12889312],"study_design_scores_gemma":[0.00004218585,0.000176317,0.0024127814,0.0041852286,0.000022367589,0.0030062378,0.012796709,0.00028784896,0.00022337798,0.12392175,0.8527924,0.00013276488],"about_ca_topic_score_codex":0.014688424,"about_ca_topic_score_gemma":0.018954948,"teacher_disagreement_score":0.015940344,"about_ca_system_score_codex":0.008478875,"about_ca_system_score_gemma":0.01638946,"threshold_uncertainty_score":0.08430159},"labels":[],"label_agreement":null},{"id":"W1987552345","doi":"10.4137/ccrpm.s10592","title":"Tobramycin Inhalation Powder (TIP): An Efficient Treatment Strategy for the Management of Chronic <i>Pseudomonas Aeruginosa</i> Infection in Cystic Fibrosis","year":2013,"lang":"en","type":"review","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"Cystic Fibrosis Research Advances","field":"Medicine","cited_by":31,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Tobramycin; Cystic fibrosis; Pseudomonas aeruginosa; Medicine; Inhalation; Antibiotics; Inhaler; Dry-powder inhaler; Intensive care medicine; Internal medicine; Asthma; Anesthesia; Microbiology; Bacteria; Biology","score_opus":0.1446739818067362,"score_gpt":0.427259425374467,"score_spread":0.28258544356773074,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W1987552345","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.37068465,0.5493746,0.035717946,0.013365336,0.0016930392,0.00085470744,0.00067397964,0.0013472191,0.026288478],"genre_scores_gemma":[0.7945146,0.16569357,0.024328854,0.0040999753,0.0010329699,0.0003177121,0.000596466,0.00009030682,0.009325713],"study_design_codex":"design_other","study_design_gemma":"systematic_review","domain_scores_codex":[0.99988854,0.000020924806,0.000008308752,0.00002090167,0.000040848543,0.000020418847],"domain_scores_gemma":[0.9999361,0.0000062022596,0.000025121979,0.0000033592487,0.000010077011,0.000019064937],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00016571565,0.00026490807,0.00038584616,0.0004805871,0.00028122237,0.0004784304,0.0002952728,0.0006884788,0.0014683743],"category_scores_gemma":[0.00015661381,0.000069553076,0.00038538134,0.00027755107,0.00022417963,0.00029463897,0.00038674046,0.0008776229,0.00092230533],"study_design_candidate":"systematic_review","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0012099858,0.00097450434,0.0025083304,0.0020036895,0.000079335514,0.0017044693,0.00012991687,0.00029893493,0.2251247,0.0011249611,0.013817795,0.7510234],"study_design_scores_gemma":[0.0017831208,0.020790681,0.0582162,0.0019775191,0.0005729308,0.038281742,0.0004966016,0.0043318374,0.20911983,0.002245996,0.66202825,0.00015537934],"about_ca_topic_score_codex":0.00052110135,"about_ca_topic_score_gemma":0.0013743129,"teacher_disagreement_score":0.0014683743,"about_ca_system_score_codex":0.0002529426,"about_ca_system_score_gemma":0.00032792834,"threshold_uncertainty_score":0.004912138},"labels":[],"label_agreement":null},{"id":"W2057304287","doi":"10.4137/ccrpm.s7049","title":"Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Roflumilast; Medicine; COPD; Weight loss; Rolipram; Internal medicine; Adverse effect; Bronchodilator; Intensive care medicine; Asthma; Obesity; Phosphodiesterase","score_opus":0.10971775414031079,"score_gpt":0.32996234456084866,"score_spread":0.22024459042053787,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2057304287","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.6281791,0.30925214,0.0031568436,0.020832784,0.0025384359,0.0007900224,0.0010305868,0.0008723893,0.033347655],"genre_scores_gemma":[0.92831707,0.051092505,0.003568031,0.0075638364,0.001432034,0.00031543738,0.0009698427,0.000032187163,0.006709092],"study_design_codex":"design_other","study_design_gemma":"observational","domain_scores_codex":[0.9999242,0.000020912963,0.000009837941,0.0000123010395,0.00001710926,0.000015582407],"domain_scores_gemma":[0.99987674,0.000026592816,0.000028833925,0.000004182167,0.000019251805,0.000044260636],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00021312152,0.00023673299,0.00061908824,0.0002370451,0.00022241253,0.00022372481,0.00022687392,0.0005506119,0.0015446527],"category_scores_gemma":[0.00043019897,0.00007483367,0.00058090204,0.00015817658,0.00009425243,0.00031615735,0.00014950089,0.0011416151,0.00039710652],"study_design_candidate":"observational","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.020915646,0.002687206,0.008672687,0.0025387725,0.00046740012,0.0020620066,0.00014035328,0.0004772883,0.04966953,0.00051991135,0.038931582,0.8729176],"study_design_scores_gemma":[0.07764823,0.078874946,0.34593362,0.0030472728,0.0030727373,0.026380641,0.0006406343,0.0070291604,0.0425291,0.0028275626,0.41176087,0.00025531638],"about_ca_topic_score_codex":0.00059935846,"about_ca_topic_score_gemma":0.0017850718,"teacher_disagreement_score":0.0015446527,"about_ca_system_score_codex":0.0003033769,"about_ca_system_score_gemma":0.0003107577,"threshold_uncertainty_score":0.005167365},"labels":[],"label_agreement":null},{"id":"W2064260812","doi":"10.4137/ccrpm.s5535","title":"Optimal Management of Severe/Refractory Asthma","year":2011,"lang":"en","type":"article","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"Asthma and respiratory diseases","field":"Medicine","cited_by":38,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Wheeze; Asthma; Intensive care medicine; Airway hyperresponsiveness; Bronchial hyperresponsiveness; Airway; Refractory (planetary science); Chronic cough; Disease; Pediatrics; Respiratory disease; Internal medicine; Anesthesia; Lung","score_opus":0.09447223854454649,"score_gpt":0.3426013525040987,"score_spread":0.24812911395955217,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2064260812","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.02550001,0.8982096,0.0078537855,0.03146796,0.0024675638,0.00021029451,0.00024039278,0.00019920521,0.033851184],"genre_scores_gemma":[0.24632794,0.7032178,0.019551083,0.014641207,0.008299509,0.00036122522,0.0005176158,0.000051622046,0.0070320363],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.99938416,0.00018316894,0.00008376885,0.000039275976,0.0002534558,0.00005623889],"domain_scores_gemma":[0.99974686,0.00007197225,0.000049344246,0.000007802101,0.000078049554,0.00004601258],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006093479,0.00036613937,0.0009647677,0.0004213716,0.00043235606,0.0008717352,0.00052173994,0.00081759033,0.0020533702],"category_scores_gemma":[0.001508476,0.00008389454,0.000420873,0.0002320753,0.00019892975,0.0005709221,0.00054281217,0.0018144593,0.0009152898],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0005294882,0.0005212117,0.0045706728,0.003631207,0.00016401811,0.0024642106,0.0002724756,0.0008653564,0.006133008,0.0040517463,0.07026943,0.90652704],"study_design_scores_gemma":[0.0007267596,0.0025721441,0.049602337,0.015609035,0.00056008133,0.020146111,0.0012541865,0.002471032,0.004738279,0.015270284,0.8869588,0.000090908565],"about_ca_topic_score_codex":0.00049201725,"about_ca_topic_score_gemma":0.0009297884,"teacher_disagreement_score":0.0020533702,"about_ca_system_score_codex":0.0003785096,"about_ca_system_score_gemma":0.00069173,"threshold_uncertainty_score":0.0068692565},"labels":[],"label_agreement":null},{"id":"W2164073715","doi":"10.4137/ccrpm.s10348","title":"Erratum for “Roflumilast, a Novel Phosphodiesterase 4 Inhibitor, for COPD Patients with a History of Exacerbations”","year":2012,"lang":"en","type":"erratum","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Roflumilast; COPD; Medicine; Phosphodiesterase inhibitor; Respiratory Medicine; Phosphodiesterase; Respiratory system; cGMP-specific phosphodiesterase type 5; Intensive care medicine; Pharmacology; Internal medicine; Sildenafil; Chemistry; Surgery","score_opus":0.08110678445568513,"score_gpt":0.3405296148479691,"score_spread":0.259422830392284,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2164073715","genre_codex":"editorial","genre_gemma":"editorial","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"editorial","genre_consensus":"editorial","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.00012952993,0.0018926079,0.00048316456,0.082104504,0.91190314,0.00001915573,0.00041278574,0.00014967627,0.0029053355],"genre_scores_gemma":[0.007874381,0.014298334,0.0046010776,0.30526242,0.46058065,0.00019150306,0.0021503165,0.0012067562,0.20383452],"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","domain_scores_codex":[0.99527293,0.0007854248,0.0009949591,0.0004627228,0.0022035746,0.0002803899],"domain_scores_gemma":[0.9814323,0.0061755935,0.0012512245,0.0006902482,0.009753802,0.0006968245],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0036702747,0.0019213312,0.0017227065,0.0025722343,0.0027316501,0.002972776,0.0021478352,0.0055150273,0.018749762],"category_scores_gemma":[0.042999487,0.00095136155,0.0020277365,0.0015815339,0.0017711695,0.002047853,0.0013930683,0.012665658,0.01589643],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000022131424,0.0000057269626,0.000044822744,0.00006215792,0.0000063074076,0.00018894904,0.00001633426,0.000018352759,0.000033948883,0.0003209445,0.9941176,0.0051627383],"study_design_scores_gemma":[0.00003295187,0.000026011228,0.00039084384,0.00034421164,0.000030586525,0.0007971617,0.000056244622,0.00012310239,0.00025916952,0.00050501636,0.99740547,0.000029241446],"about_ca_topic_score_codex":0.015834998,"about_ca_topic_score_gemma":0.021659723,"teacher_disagreement_score":0.018749762,"about_ca_system_score_codex":0.0032762322,"about_ca_system_score_gemma":0.0056261183,"threshold_uncertainty_score":0.06272423},"labels":[],"label_agreement":null},{"id":"W3094465086","doi":"10.1177/1179548420966242","title":"Asthma and COVID-19: What do we know now","year":2020,"lang":"en","type":"review","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"COVID-19 Clinical Research Studies","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"University of Ottawa","funders":"","keywords":"Asthma; Coronavirus disease 2019 (COVID-19); Pandemic; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Medicine; Intensive care medicine; 2019-20 coronavirus outbreak; Identification (biology); Asthma management; Disease; Immunology; Virology; Pathology; Infectious disease (medical specialty)","score_opus":0.21901070191617333,"score_gpt":0.4908033329930824,"score_spread":0.27179263107690904,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3094465086","genre_codex":"review","genre_gemma":"review","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"review","genre_consensus":"review","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.000039934137,0.9984818,0.000026614991,0.0010314927,0.00017606349,0.0000023374478,0.000017403776,0.0000024332978,0.0002219267],"genre_scores_gemma":[0.00041048884,0.9986645,0.0000634763,0.00052814605,0.00023092749,0.0000037430682,0.000017923805,8.83662e-7,0.000079954196],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9992687,0.00018852053,0.00016844406,0.00011777326,0.0002002193,0.000056292756],"domain_scores_gemma":[0.9941598,0.0043887454,0.00054017745,0.000087145214,0.0006626912,0.00016139219],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0018199031,0.00071245414,0.0022128546,0.0028379315,0.0004774616,0.002522614,0.0010326431,0.0023674534,0.0065474943],"category_scores_gemma":[0.0060709007,0.0004376253,0.0012644562,0.0034339272,0.00083416817,0.0037069991,0.0009978713,0.0024527642,0.0014386469],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.000153114,0.000059257673,0.00052932574,0.1058669,0.0003790215,0.00017327964,0.00023206092,0.00016801905,0.00037251314,0.0040810877,0.035554793,0.85243064],"study_design_scores_gemma":[0.000030696214,0.00012583564,0.0020240182,0.10671126,0.0010552901,0.0013164754,0.00046528163,0.00008330277,0.00016000411,0.0037604228,0.8842219,0.00004541255],"about_ca_topic_score_codex":0.003518585,"about_ca_topic_score_gemma":0.005766159,"teacher_disagreement_score":0.0065474943,"about_ca_system_score_codex":0.000955965,"about_ca_system_score_gemma":0.004289342,"threshold_uncertainty_score":0.021903515},"labels":[],"label_agreement":null},{"id":"W3147193104","doi":"10.1177/11795484211006050","title":"Delphi Consensus Recommendations on Management of Dosing, Adverse Events, and Comorbidities in the Treatment of Idiopathic Pulmonary Fibrosis with Nintedanib","year":2021,"lang":"en","type":"article","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"route_ca_aff":true,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"McMaster University","funders":"National Center for Advancing Translational Sciences; Boehringer Ingelheim","keywords":"Nintedanib; Medicine; Idiopathic pulmonary fibrosis; Adverse effect; Intensive care medicine; Dosing; Tolerability; Internal medicine; Lung","score_opus":0.07506965146366566,"score_gpt":0.348781496039646,"score_spread":0.2737118445759803,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W3147193104","genre_codex":"commentary","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":null,"domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.047497522,0.015707968,0.17680973,0.6013396,0.01624494,0.05908933,0.0033113076,0.0009437118,0.07905589],"genre_scores_gemma":[0.28044692,0.017606128,0.5178012,0.09868787,0.0024959217,0.06944354,0.0028160845,0.00037630816,0.010325998],"study_design_codex":"design_other","study_design_gemma":"qualitative","domain_scores_codex":[0.63730884,0.2724099,0.04916438,0.006579659,0.02424612,0.010291112],"domain_scores_gemma":[0.70791477,0.15703973,0.014680627,0.009018778,0.10159806,0.009747994],"candidate_categories":["metaresearch"],"consensus_categories":[],"category_scores_codex":[0.31179452,0.0028593577,0.0020896033,0.005399668,0.005271153,0.005635094,0.005288305,0.009189868,0.008053519],"category_scores_gemma":[0.30294314,0.0020810924,0.006463398,0.0030116173,0.0062755793,0.006943884,0.014354891,0.010313512,0.0035538108],"study_design_candidate":"qualitative","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0010640353,0.0006873602,0.008148849,0.029858932,0.0010804859,0.0017532865,0.11805656,0.008313597,0.0066543445,0.045489926,0.31414127,0.46475136],"study_design_scores_gemma":[0.0012152503,0.0009853545,0.008622669,0.08468961,0.0010261149,0.0017863142,0.074512236,0.010557715,0.0043123644,0.102962546,0.70810413,0.0012257562],"about_ca_topic_score_codex":0.005911641,"about_ca_topic_score_gemma":0.0046907435,"teacher_disagreement_score":0.31179452,"about_ca_system_score_codex":0.011910548,"about_ca_system_score_gemma":0.053581066,"threshold_uncertainty_score":0.8486799},"labels":[],"label_agreement":null},{"id":"W4225985151","doi":"10.1177/11795484221075492","title":"Detection of Anti-SARS-CoV-2 Nucleocapsid and Spike Antibodies in Patients with Coronavirus Disease 2019 in Japan","year":2022,"lang":"en","type":"article","venue":"Clinical Medicine Insights Circulatory Respiratory and Pulmonary Medicine","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":true,"route_ca_venue":false,"route_about_ca":false,"ca_institutions":"","funders":"Pfizer Japan; Chugai Pharmaceutical; Eisai Canada; Astellas Foundation for Research on Metabolic Disorders; Abbott Japan; Bristol-Myers Squibb; Takeda Pharmaceutical Company; Mitsubishi Tanabe Pharma Corporation","keywords":"Serology; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Coronavirus disease 2019 (COVID-19); Antibody; Coronavirus; Rheumatoid arthritis; Virology; Internal medicine; Immunology; Disease; Infectious disease (medical specialty)","score_opus":0.09078832044399497,"score_gpt":0.37877435786275954,"score_spread":0.28798603741876455,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4225985151","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"metacan-v3-hybrid-931329e0061c","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9996525,0.000110829475,0.00002886347,0.000013062634,0.000004103999,0.0000044552094,0.000024326186,0.0000014499401,0.00016049833],"genre_scores_gemma":[0.999775,0.000050178147,0.000041729945,0.00002270253,0.000008259682,0.000004007949,0.000059327074,6.225855e-7,0.000038273472],"study_design_codex":"observational","study_design_gemma":"observational","domain_scores_codex":[0.99943477,0.00012165733,0.00009352331,0.00014025072,0.00009869546,0.00011114698],"domain_scores_gemma":[0.9991654,0.00011683229,0.0002870969,0.000032871732,0.00017216904,0.00022577302],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00053505966,0.00048309373,0.0004686619,0.00073952536,0.00066927646,0.00059798243,0.00025438913,0.000611897,0.0007314741],"category_scores_gemma":[0.001330915,0.0004121185,0.00039377282,0.00063386594,0.00046919804,0.00043634168,0.0003922642,0.0003707052,0.00022159463],"study_design_candidate":"observational","study_design_consensus":"observational","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.00009815386,0.000029350134,0.997635,0.000011323041,0.000013900615,0.00030747053,0.00017052674,0.000011784885,0.0011403996,0.0000033056363,0.00003531733,0.00054344564],"study_design_scores_gemma":[0.000013364171,0.00017875148,0.9980446,0.000005285034,0.000022049031,0.0010513489,0.00034567775,0.00008987056,0.00013199402,0.000004752108,0.000108476466,0.0000038175813],"about_ca_topic_score_codex":0.005581434,"about_ca_topic_score_gemma":0.004751527,"teacher_disagreement_score":0.005581434,"about_ca_system_score_codex":0.00042398478,"about_ca_system_score_gemma":0.0003401617,"threshold_uncertainty_score":0.011097908},"labels":[],"label_agreement":null}]}